Additionally, it has also been reported that an RXR agonist, AGN194204, potentiated the anti-proliferative and pro-apoptotic responses of breast cancer cell lines to PPAR agonists through RXR-PPAR heterodimer [44]. This evidence concerns the gene PPARA and breast carcinoma.